Prevention of immune-mediated transfusion reactions

Administering anti-B-cell antibodies before transfusions inhibits B cell activation, effectively reducing alloimmunization and immune-mediated reactions in blood transfusions, enhancing transfusion safety for patients with conditions like sickle cell disease and thalassemia.

WO2026019811A1 Publication Date: 2026-01-22NEW YORK BLOOD CENT INC
2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/037723
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-08
Filing Date
2025-07-15
Publication Date
2026-01-22

AI Technical Summary

Technical Problem

Blood transfusions are complicated by immune-mediated reactions, particularly alloimmunization, which can lead to complications such as hemolytic transfusion reactions and platelet refractoriness, especially in patients with conditions like sickle cell disease and thalassemia, due to the recipient's immune system reacting against foreign antigens in transfused blood components.

Method used

Administering anti-B-cell antibodies, such as anti-CD20, anti-CD19, or anti-BAFF-R antibodies, prior to transfusions to target and inhibit B cell activation, thereby reducing the immune response against transfused blood products.

Benefits of technology

This approach significantly reduces the production of antibodies against red blood cells and platelets, mitigating alloimmunization and other immune-mediated transfusion reactions, improving transfusion efficacy and safety.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are methods of preventing or treating alloimmunization in a subject in need thereof, the method comprising administering an anti-B-cell antibody to the subject prior to the subject receiving a blood transfusion.
Need to check novelty before this filing date? Find Prior Art